Vanda Pharmaceuticals Inc. (VNDA) Stock Price

VNDAStock

$5.29+12.55%52W

Market Cap$319.85M

P/E—

PEG Ratio2.23

Div yield—

Beta0.66

VNDA Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-47.18%

Price vs S&P 500 (4W)-0.39%

PEG Ratio2.23

VGM Score45.94

Book Value / Share (Quarterly)$4.67

P/TBV (Annual)2.48x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-5.29%

Cash Flow / Share (Quarterly)$-2.28

Price vs S&P 500 (YTD)-52.84%

Gross Margin (TTM)94.18%

Net Profit Margin (TTM)-109.99%

EPS (TTM)$-4.05

10-Day Avg Trading Volume0.79M

EPS Excl Extra (TTM)$-4.05

Revenue Growth (5Y)-2.73%

EPS (Annual)$-3.74

ROI (Annual)-65.88%

Gross Margin (Annual)93.96%

Net Profit Margin (5Y Avg)-19.08%

Cash / Share (Quarterly)$3.36

Revenue Growth QoQ (YoY)3.35%

ROA (Last FY)-45.09%

Revenue Growth TTM (YoY)8.16%

EBITD / Share (TTM)$-2.59

ROE (5Y Avg)-12.53%

Operating Margin (TTM)-73.64%

Cash Flow / Share (Annual)$-1.87

P/B Ratio1.08x

P/B Ratio (Quarterly)1.45x

Net Income / Employee (Annual)$-413,600

EV / Revenue (TTM)1.18x

ROA (TTM)-44.60%

EV / EBITDA (TTM)201.38x

EPS Incl Extra (Annual)$-3.74

Current Ratio (Annual)2.39x

Quick Ratio (Quarterly)1.91x

3-Month Avg Trading Volume1.00M

52-Week Price Return12.55%

EV / Free Cash Flow (Annual)-31.46x

Revenue / Employee (TTM)$408,600

Tangible BV / Share (Quarterly)$2.75

P/S Ratio (Annual)1.41x

Asset Turnover (Annual)0.44x

52-Week High$9.94

Operating Margin (5Y Avg)-15.89%

EPS Excl Extra (Annual)$-3.74

CapEx CAGR (5Y)-11.13%

Tangible BV CAGR (5Y)-13.41%

26-Week Price Return-35.25%

Quick Ratio (Annual)2.19x

13-Week Price Return-20.33%

Total Debt / Equity (Annual)0.02x

Current Ratio (Quarterly)2.16x

Enterprise Value$257.76M

Revenue / Share Growth (5Y)-4.00%

Asset Turnover (TTM)0.41x

Book Value / Share Growth (5Y)-7.68%

Revenue / Employee (Annual)$405,500

Inventory Turnover (Annual)7.29x

Pretax Margin (Annual)-64.16%

Cash / Share (Annual)$4.46

3-Month Return Std Dev40.94%

Gross Margin (5Y Avg)92.30%

Net Income / Employee (TTM)$-449,400

ROE (Last FY)-67.38%

EPS Basic Excl Extra (Annual)$-3.74

P/FCF (TTM)40.25x

Receivables Turnover (TTM)4.29x

EV / Free Cash Flow (TTM)-20.52x

Total Debt / Equity (Quarterly)0.03x

EPS Incl Extra (TTM)$-4.05

Receivables Turnover (Annual)4.25x

ROI (TTM)-60.43%

P/S Ratio (TTM)1.40x

Pretax Margin (5Y Avg)-10.44%

Revenue / Share (Annual)$3.67

Tangible BV / Share (Annual)$3.55

Price vs S&P 500 (52W)-6.01%

Year-to-Date Return-40.02%

5-Day Price Return-0.75%

EPS Normalized (Annual)$-3.74

ROA (5Y Avg)-8.20%

Net Profit Margin (Annual)-102.02%

Month-to-Date Return3.73%

Cash Flow / Share (TTM)$0.25

EBITD / Share (Annual)$-2.45

Operating Margin (Annual)-69.95%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-12.23%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-4.05

P/TBV (Quarterly)2.47x

P/B Ratio (Annual)1.59x

Inventory Turnover (TTM)7.00x

Pretax Margin (TTM)-68.74%

Book Value / Share (Annual)$5.54

Price vs S&P 500 (13W)-22.29%

Beta0.66x

P/FCF (Annual)24.51x

Revenue / Share (TTM)$3.66

ROE (TTM)-61.41%

52-Week Low$4.27

vGradeC

gGradeC

mGradeC

vgmGradeC

VNDA Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 5, 2026	-$0.59	-$1.04	-77.02%(-$0.45)
Q1 2026	May 6, 2026	-$0.69	-$0.82	-19.27%(-$0.13)
Q4 2025	Feb 11, 2026	-$1.32	-$2.39	-80.38%(-$1.07)
Q3 2025	Oct 29, 2025	-$0.45	-$0.38	+16.18%(+$0.07)
Q2 2025	Jul 31, 2025	-$0.36	-$0.46	-28.97%(-$0.10)

VNDA Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.00

Industry Peers — Pharmaceuticals(570)

Symbol	Value Score	Growth Score	Momentum Score	Price
VNDAVanda Pharmaceuticals Inc.	C	C	C	$5.29
LLYEli Lilly & Co.	D	B	C	$1174.61
JNJJohnson & Johnson	D	C	B	$268.04
ABBVABBVIE INC.	D	C	B	$255.48
MRKMerck & Co., Inc.	D	C	B	$148.35
NVSNovartis AG	C	C	C	$153.81
AZNAstraZeneca PLC	C	B	C	$162.70
NVONovo-Nordisk A/S	B	C	C	$45.61
ABTAbbott Laboratories	C	C	C	$112.47
PFEPfizer Inc.	C	D	B	$27.96
VRTXVertex Pharmaceuticals Inc	D	C	B	$541.69
BMYBristol-Myers Squibb Co.	B	B	B	$66.58
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$44.82
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$50.82
REGNRegeneron Pharmaceuticals Inc	C	C	B	$794.19
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	B	$18.03
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$36.44
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	$366.73
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$60.85
ZTSZOETIS INC.	C	C	D	$77.34
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$237.10
INSMInsmed, Inc.	F	A	C	$118.54
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$34.71
UTHRUnited Therapeutics Corp	C	C	B	$515.46
GMABGenmab A/S ADS	C	C	B	$33.23
VTRSViatris Inc. Common Stock	B	C	B	$16.34
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$247.91
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$244.54
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$76.60
BMRNBioMarin Pharmaceuticals Inc	C	C	B	$64.67
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	B	$533.76
CORTCorcept Therapeutics Inc.	F	C	B	$113.88
ELANElanco Animal Health Incorporated Common Stock	C	B	C	$24.11
ARWRArrowhead Research Corporation	D	A	B	$84.91
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.73
AXSMAxsome Therapeutics, Inc	D	B	C	$199.02
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.18
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$61.05
CYTKCytokinetics Inc.	F	D	C	$72.09
ABVXAbivax SA American Depositary Shares	—	—	C	$113.35
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$344.75
PTGXProtagonist Therapeutics, Inc	F	B	B	$144.33
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.84
TGTXTG Therapeutics, Inc.	D	B	B	$53.93
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	$90.36
ALKSAlkermes Inc. plc	D	C	B	$47.41
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$107.17
ERASErasca, Inc. Common Stock	—	—	A	$18.03
TVTXTravere Therapeutics, Inc. Common Stock	F	B	A	$65.67
BLTEBelite Bio, Inc American Depositary Shares	—	—	C	$151.72

About Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals is a biopharmaceutical company developing therapies for neurology and psychiatry conditions with significant unmet medical needs. Its commercial portfolio includes HETLIOZ (for Non-24-Hour Sleep-Wake Disorder and Smith-Magenis Syndrome), Fanapt (schizophrenia), and PONVORY, with Fanapt generating the majority of revenue. The company operates primarily in the United States, with additional markets in Europe, Israel, and Canada, and maintains a pipeline of development-stage candidates.